Php-303    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
231Alpha-1-antitrypsin deficiency1

231. Alpha-1-antitrypsin deficiency    [ 83 clinical trials,   89 drugs,   (DrugBank: 16 drugs),   35 drug target genes,   46 drug target pathways]
Searched query = "Alpha-1-antitrypsin deficiency", "AATD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 83 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-002501-22-GB
(EUCTR)
04/05/202030/10/2019A Multi-Center, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Tolerability of the Neutrophil Elastase Inhibitor PHP-303 in Adults with Alpha-1 Antitrypsin Deficiency (AATD)A Multi-Center, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Tolerability of the Neutrophil Elastase Inhibitor PHP-303 in Adults with Alpha-1 Antitrypsin Deficiency (AATD) Alpha-1 Antitrypsin Deficiency;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Product Code: PHP-303
INN or Proposed INN: Not applicable
Other descriptive name: (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile
pH Pharma Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2United Kingdom